Section 9 The party responsible for placing on the market 1 Medicinal products that are placed on the market within the purview of the present Act shall bear the name or the company and the address of the pharmaceutical entrepreneur. This shall not apply to medicinal products intended for use in a clinical trial on human subjects. Section 10 Labelling 1 Finished medicinal products that are medicinal products within the meaning of Section 2 sub-section 1 or sub-section 2 number 1, and are not intended for clinical trials on human beings or exempted from the obligation to obtain a marketing authorisation, pursuant to Section 21 sub-section 2 number 1a, 1b or 6, may only be placed on the market within the purview of the present Act provided that the following information is displayed on the containers and, where used, on the outer packaging in easily legible and indelible characters, in easily comprehensible German and pursuant to the details referred to in Section 11a:
The following words and phrases, as used in this chapter, shall have the following meanings, unless the context otherwise requires: Such controlled drugs are classifiable as amphetamine-type, barbiturate-type, cannabis-type, cocaine-type, hallucinogenic, morphine-type and other stimulant and depressant drugs.
Metal, wooden, acrylic, glass, stone, plastic or ceramic pipes with screens, permanent screens, hashish heads or punctured metal bowls; water pipes; carburetion tubes and devices; smoking and carburetion masks; roach clips: Marijuana does not include the mature stalks of such plant, fiber produced from such stalks, oil or cake made from the seeds of such plant, any other compound, manufacture, salt, derivative, mixture or preparation of such mature stalks, except the resin extracted therefrom, fiber, oil, or cake, the sterilized seed of such plant which is incapable of germination, or industrial hemp, as defined in 7 USCas amended from time to time.
Datura stramonium; hyoscyamus niger; atropa belladonna, or the alkaloids atropine; hyoscyamine; belladonnine; apatropine; or any mixture of these alkaloids such as daturine, or the synthetic homatropine or any salts of these alkaloids, except that any drug or preparation containing any of the above-mentioned substances which is permitted by federal food and drug laws to be sold or dispensed without a prescription or written order shall not be a controlled substance; amyl nitrite; the following volatile substances to the extent that said chemical substances or compounds containing said chemical substances are sold, prescribed, dispensed, compounded, possessed or controlled or delivered or administered to another person with the purpose that said chemical substances shall be breathed, inhaled, sniffed or drunk to induce a stimulant, depressant or hallucinogenic effect upon the higher functions of the central nervous system: In an obsolete reference in Subdiv.
Annotations to former section Applied to prosecution under Sec. Annotations to present section: A clearly not intended as an exhaustive or exclusive list.CHAPTER 17 Investments ASSIGNMENT CLASSIFICATION TABLE (BY TOPIC) Topics Questions *This material is dealt with in an Appendix to the chapter.
ASSIGNMENT CLASSIFICATION TABLE (BY LEARNING OBJECTIVE) Explain who uses derivatives and why. *9. Understand the basic guidelines for accounting for .
All students enrolling in Math 17A are required to satisfy the MPR. The MPR can only be satisfied by Passing the Math Placement Exam with an overall score of at least 30 AND a trig score of at least 2.
Apr 22, · The hilarious thing will be Humans on Tuchanka. Sure, the megafauna might be tougher, but it's still less hostile than Planet.
Of course, then there's the political ramifications when some well meaning Gaian scientist publishes the cure for the genophage and a huge technical dissertation on how to make Krogans immune to it and any derivatives.*. Sec. 21a (Formerly Sec.
). Prior regulations continued. Regulations promulgated under chapter of the general statutes, revision of , as amended, and chapters a and b of the supplement thereto, in effect on October 1, , shall, unless clearly in conflict with the provisions of this chapter, continue in effect until superseded by regulations hereunder.
§ a Reports to be made by certain OTC derivatives dealers. (a)Filing of quarterly reports. (3) Supporting schedules shall include, from Part IIB of Form XA-5 (§ of this chapter), a Computation of Net Capital under § c (5) The annual audit report shall be filed not.
(i) Every OTC derivatives dealer shall file Part IIB of Form XA-5 (§ of this chapter) within 17 business days after the end of each calendar quarter and within 17 business days after the date selected for the annual audit of financial statements where said date is other than the end of the calendar quarter.